(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.55%) $78.54
(2.05%) $2.19
(0.09%) $2 310.70
(0.54%) $26.84
(0.02%) $965.50
(-0.35%) $0.929
(-1.39%) $10.84
(-0.13%) $0.797
(0.52%) $91.61
-0.57% € 140.80
Live Chart Being Loaded With Signals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 34 481.00 |
Średni wolumen | 62 873.00 |
Kapitalizacja rynkowa | 218.27B |
EPS | €0.881 ( 2023-09-30 ) |
Następna data zysków | ( €0 ) 2024-06-19 |
Last Dividend | €0.718 ( 2023-08-10 ) |
Next Dividend | €0 ( N/A ) |
P/E | 37.45 |
ATR14 | €0.0890 (0.06%) |
Wolumen Korelacja
AstraZeneca PLC Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AstraZeneca PLC Korelacja - Waluta/Towar
AstraZeneca PLC Finanse
Annual | 2023 |
Przychody: | €45.81B |
Zysk brutto: | €37.54B (81.95 %) |
EPS: | €3.84 |
FY | 2023 |
Przychody: | €45.81B |
Zysk brutto: | €37.54B (81.95 %) |
EPS: | €3.84 |
FY | 2022 |
Przychody: | €44.35B |
Zysk brutto: | €31.96B (72.06 %) |
EPS: | €2.12 |
FY | 2021 |
Przychody: | €37.42B |
Zysk brutto: | €24.98B (66.76 %) |
EPS: | €0.0800 |
Financial Reports:
No articles found.
AstraZeneca PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.764 (N/A) |
€0 (N/A) |
€1.628 (N/A) |
€0 (N/A) |
€0.718 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.540 | 2004-02-18 |
Last Dividend | €0.718 | 2023-08-10 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | €40.56 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.08 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.82 | |
Div. Directional Score | 8.92 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NWO.DE | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% | |
AAD.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
GIL.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
REP.DE | Ex Dividend Knight | 2023-07-04 | Semi-Annually | 0 | 0.00% | |
BAC.DE | Ex Dividend Knight | 2023-10-09 | Quarterly | 0 | 0.00% | |
INH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
SZU.DE | Ex Dividend Knight | 2023-07-14 | Annually | 0 | 0.00% | |
COK.DE | Ex Dividend Knight | 2023-06-15 | Annually | 0 | 0.00% | |
LQZ.F | Ex Dividend Knight | 2023-09-07 | Annually | 0 | 0.00% | |
VVD.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.133 | 1.500 | 7.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0619 | 1.200 | 7.94 | 9.52 | [0 - 0.3] |
returnOnEquityTTM | 0.168 | 1.500 | 9.25 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.706 | -1.000 | 2.94 | -2.94 | [0 - 1] |
currentRatioTTM | 0.886 | 0.800 | -0.572 | -0.458 | [1 - 3] |
quickRatioTTM | 0.661 | 0.800 | -0.820 | -0.656 | [0.8 - 2.5] |
cashRatioTTM | 0.271 | 1.500 | 9.60 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.338 | -1.500 | 4.37 | -6.56 | [0 - 0.6] |
interestCoverageTTM | 5.33 | 1.000 | 9.14 | 9.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.26 | 2.00 | 7.91 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.73 | 2.00 | 8.13 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.923 | -1.500 | 6.31 | -9.46 | [0 - 2.5] |
grossProfitMarginTTM | 0.820 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.184 | 1.000 | 8.32 | 8.32 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.281 | 1.000 | 9.55 | 9.55 | [0.2 - 2] |
assetTurnoverTTM | 0.465 | 0.800 | -0.230 | -0.184 | [0.5 - 2] |
Total Score | 11.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 37.09 | 1.000 | 6.35 | 0 | [1 - 100] |
returnOnEquityTTM | 0.168 | 2.50 | 9.52 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.73 | 2.00 | 8.76 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.503 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.26 | 2.00 | 7.91 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.706 | 1.500 | 2.94 | -2.94 | [0 - 1] |
pegRatioTTM | 2.80 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.204 | 1.000 | 7.41 | 0 | [0.1 - 0.5] |
Total Score | 6.82 |
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej